Free Trial
NASDAQ:HOOK

Hookipa Pharma Q3 2023 Earnings Report

Hookipa Pharma logo
$1.62 +0.10 (+6.58%)
Closing price 04:00 PM Eastern
Extended Trading
$1.59 -0.03 (-1.85%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hookipa Pharma EPS Results

Actual EPS
-$1.70
Consensus EPS
-$2.30
Beat/Miss
Beat by +$0.60
One Year Ago EPS
N/A

Hookipa Pharma Revenue Results

Actual Revenue
$6.87 million
Expected Revenue
$3.39 million
Beat/Miss
Beat by +$3.48 million
YoY Revenue Growth
N/A

Hookipa Pharma Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 9, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Hookipa Pharma's Q1 2025 earnings is scheduled for Wednesday, August 6, 2025

Hookipa Pharma Earnings Headlines

Hookipa Pharma (HOOK) Receives a Hold from RBC Capital
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
Hookipa Pharma Drops Poolbeg Takeover Bid
See More Hookipa Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hookipa Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hookipa Pharma and other key companies, straight to your email.

About Hookipa Pharma

Hookipa Pharma (NASDAQ:HOOK)., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

View Hookipa Pharma Profile

More Earnings Resources from MarketBeat